Clinical Trial Update: Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status [Phase 2]

View source ↗

Summary

Phase 2 study evaluating neratinib in combination with trastuzumab or cetuximab for metastatic colorectal cancer with wild-type KRAS/NRAS/BRAF/PIK3CA, stratifie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• Trastuzumab (trastuzumab)
• neratinib (neratinib)

Snippet

Sponsor: NSABP Foundation Inc | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: UNKNOWN